文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 外语学习 > 英语学习 > China Coronary Secondary Prevention Study
侵权投诉

China Coronary Secondary Prevention Study

China Coronary Secondary Prevention Study

China Coronary Secondary Prevention Study (CCSPS)- Lipid-regulating

therapy with Xuezhikang for Secondary Prevention of Coronary Heart Disease

China Coronary Secondary Prevention Study Group

[Abstract]

Objective. To determine whether lipid-regulating therapy with Xuezhikang reduces the risk of coronary events and all-cause mortality in Chinese patients with coronary heart disease (CHD).

Methods. This study was a multi-centre, randomized, double blind, placebo controlled, long term follow-up clinical trial designed to compare the effect of Xuezhikang and placebo capsules. The study was conducted at 65 centers in 19 provinces in China. 4870 CHD patients, aged 18 to 75 years, with definite myocardial infarction history who had baseline cholesterol levels between 4.40 and 6.47mmol/L were recruited between May 1996 and December 2000. Patients were randomly assigned to receive treatment with Xuezhikang capsule, 0.6g Bid or matching placebo and were followed for a mean of 4 years. The primary endpoints were coronary events, including nonfatal myocardial infarction and CHD death. The secondary endpoint, analyzed by the time of first events, was all cause death. Results. Xuezhikang significantly reduced the risk of CHD events by 45.1% (P<0.0001) compared with placebo(5.72% vs 10.41%). The relative risk reduction of CHD death and nonfatal myocardial infarction was 31.0% (3.79% vs 5.49%) and 60.8% (1.93% vs.4.92%) respectively (p<0.0001). Xuezhikang resulted in a 33.0 %(P=0.0003) risk reduction in the secondary endpoint of all-cause mortality compared to placebo (5.19% vs. 7.74% ),in which there was a 54.7% (P=0.0138) risk reduction in malignancy death. Adverse effects and abnormal laboratory parameters did not differ significantly between the two groups.

Conclusion Compared with placebo, Xuezhikang can significantly decrease the incidence of nonfatal myocardial infarction and CHD death, as well as malignancy death and all-cause mortality in Chinese CHD patients.

[Key Words] Xuezhikang capsule; blood lipid; coronary heart disease; secondary prevention

-----------------------

National scientific and technological project in Chinese Ninth Five year plan.(96-906-02-10)

Correspondence to Lu Zongliang,Chinese Academy of Medical Science, Peking Union Medical Collage, Fuwai Hospital,100037,Beijing,China

第1页

你可能喜欢

热门文档

相关文档

  • China Coronary Secondary Prevention Study (CCSPS) -...

    China Coronary Secondary Prevention Study (CCSPS) - Lipid-regulating_英语学习_外语学习_教育专区 暂无评价 0人阅读 0次下载 举报文档 China Coronary ...

  • Feasibility Study of Secondary Polymer Flooding in ...

    Feasibility Study of W... 18页 免费 China Coronary Seconda... 暂无评价...After secondary polymer flooding, just as shown in Table 3, fractional flow...

  • 血脂康胶囊临床应用中国专家共识

    (二)冠心病二级预防研究 1.中国冠心病二级预防研究(China Coronary Secondary Prevention Study, CCSPS)[26-27] 目前这是我国惟一一项对冠心病二级预防的大规模,前瞻...

  • 中国成人血脂异常防治指南zly

    9. 中国冠心病二级预防研究(China coronary secondary prevention study,CCSPS): 研究表明老年患者、合并糖尿病或高血压的患者治疗后获益更显著。 特殊人群的降脂临床...

  • 3.冠心病二级预防--陈韵岱

    我国从1996年至2000年进 行的中国冠心病二级预防研究(China Coronary Secondary Prevention Study CCSPS)是针对中国冠心病患者进行的冠心病二级预防试验, 是一项为多...

  • methods of secondary prevention

    Chapter 6 Secondary synt... 暂无评价 37页 免费 Spoofing Prevention Meth... 暂无评价 18页 免费 China Coronary Secondary... 暂无评价 11页 免费...

  • 血脂与冠心病

    血脂与冠心病 ——来自中国循证医学的证据解放军总医院 叶平 CCSPS 中国冠心病二级预防研究 China Coronary Secondary Prevention Study (CCSPS) --血脂康调整血脂对...

  • Stroke in China epidemiology, prevention, and manag...

    coronary heart disease.4 In the past 20 years,...“primary prevention”, “secondary prevention”, ...study in China and it showed the lowest average...

  • 某产品调整血脂

    血脂康调整血脂 对冠心病二级预防的研究 China Coronary Secondary Prevention Study (CCSPS) CCSPS) 国家九五攻关课题编号:96-906-02国家九五攻关课题编号:96-906-...

  • 方便资料被

    中国冠心病二级预防研究 China Coronary Secondary Prevention Study 中国老年冠心病人群唯一循证医学研究(国家九五攻关课题) 课题牵头单位:阜外心血管病医院课题协作单位:...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email